Works by Leiter, Lawrence A.

Results: 212
    1

    Weight management using meal replacements and cardiometabolic risk reduction in individuals with pre‐diabetes and features of metabolic syndrome: A systematic review and meta‐analysis of randomized controlled trials.

    Published in:
    Obesity Reviews, 2024, v. 25, n. 7, p. 1, doi. 10.1111/obr.13751
    By:
    • Noronha, Jarvis C.;
    • Nishi, Stephanie K.;
    • Khan, Tauseef A.;
    • Blanco Mejia, Sonia;
    • Kendall, Cyril W. C.;
    • Kahleová, Hana;
    • Rahelić, Dario;
    • Salas‐Salvadó, Jordi;
    • Leiter, Lawrence A.;
    • Lean, Michael E. J.;
    • Sievenpiper, John L.
    Publication type:
    Article
    2

    Risk of new‐onset diabetes and efficacy of pharmacological weight loss therapy.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4441, doi. 10.1111/dom.15798
    By:
    • Moura, Filipe A.;
    • Bellavia, Andrea;
    • Berg, David D.;
    • Melloni, Giorgio E. M.;
    • Feinberg, Mark W.;
    • Leiter, Lawrence A.;
    • Bohula, Erin A.;
    • Morrow, David A.;
    • Scirica, Benjamin A.;
    • Wiviott, Stephen D.;
    • Sabatine, Marc S.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10

    Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 704, doi. 10.1111/dom.14634
    By:
    • Raubenheimer, Peter J.;
    • Cushman, William C.;
    • Avezum, Alvaro;
    • Basile, Jan;
    • Conget, Ignacio;
    • Dagenais, Gilles;
    • Hoover, Anastasia;
    • Jansky, Petr;
    • Lanas, Fernando;
    • Leiter, Lawrence A.;
    • Lopez‐Jaramillo, Patricio;
    • Pogosova, Nana;
    • Probstfield, Jeffrey;
    • Rao‐Melacini, Purnima;
    • Rydén, Lars;
    • Sheu, Wayne H.‐H.;
    • Temelkova‐Kurktschiev, Theodora;
    • C. Gerstein, Hertzel
    Publication type:
    Article
    11
    12
    13
    14

    Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 29, doi. 10.1111/dom.14179
    By:
    • Cahn, Avivit;
    • Wiviott, Stephen D.;
    • Mosenzon, Ofri;
    • Murphy, Sabina A.;
    • Goodrich, Erica L.;
    • Yanuv, Ilan;
    • Rozenberg, Aliza;
    • Wilding, John P. H.;
    • Leiter, Lawrence A.;
    • Bhatt, Deepak L.;
    • McGuire, Darren K.;
    • Litwak, Leon;
    • Kooy, Adriaan;
    • Gause‐Nilsson, Ingrid A. M.;
    • Fredriksson, Martin;
    • Langkilde, Anna Maria;
    • Sabatine, Marc S.;
    • Raz, Itamar
    Publication type:
    Article
    15

    Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 12, p. 2487, doi. 10.1111/dom.14160
    By:
    • Verma, Subodh;
    • McGuire, Darren K.;
    • Bain, Stephen C.;
    • Bhatt, Deepak L.;
    • Leiter, Lawrence A.;
    • Mazer, C. David;
    • Monk Fries, Tea;
    • Pratley, Richard E.;
    • Rasmussen, Søren;
    • Vrazic, Hrvoje;
    • Zinman, Bernard;
    • Buse, John B.
    Publication type:
    Article
    16

    The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 9, p. 1690, doi. 10.1111/dom.14079
    By:
    • Leiter, Lawrence A.;
    • Bain, Stephen C.;
    • Bhatt, Deepak L.;
    • Buse, John B.;
    • Mazer, C. David;
    • Pratley, Richard E.;
    • Rasmussen, Søren;
    • Ripa, Maria Sejersten;
    • Vrazic, Hrvoje;
    • Verma, Subodh
    Publication type:
    Article
    17

    Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1357, doi. 10.1111/dom.14041
    By:
    • Cahn, Avivit;
    • Raz, Itamar;
    • Bonaca, Marc;
    • Mosenzon, Ofri;
    • Murphy, Sabina A.;
    • Yanuv, Ilan;
    • Rozenberg, Aliza;
    • Wilding, John P. H.;
    • Bhatt, Deepak L.;
    • McGuire, Darren K.;
    • Gause‐Nilsson, Ingrid A. M.;
    • Fredriksson, Martin;
    • Johansson, Peter A.;
    • Jermendy, Gyorgy;
    • Hadjadj, Samy;
    • Langkilde, Anna Maria;
    • Sabatine, Marc S.;
    • Wiviott, Stephen D.;
    • Leiter, Lawrence A.
    Publication type:
    Article
    18

    Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2020, v. 22, n. 7, p. 1122, doi. 10.1111/dom.14011
    By:
    • Bajaj, Harpreet S.;
    • Raz, Itamar;
    • Mosenzon, Ofri;
    • Murphy, Sabina A.;
    • Rozenberg, Aliza;
    • Yanuv, Ilan;
    • Bhatt, Deepak L.;
    • Leiter, Lawrence A.;
    • McGuire, Darren K.;
    • Wilding, John P. H.;
    • Gause‐Nilsson, Ingrid A. M.;
    • Sabatine, Marc S.;
    • Wiviott, Stephen D.;
    • Cahn, Avivit
    Publication type:
    Article
    19
    20
    21
    22
    23

    The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double‐blind, randomized, controlled, acute feeding, equivalence trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2361, doi. 10.1111/dom.13374
    By:
    • Noronha, Jarvis C.;
    • Braunstein, Catherine R.;
    • Glenn, Andrea J.;
    • Khan, Tauseef A.;
    • Viguiliouk, Effie;
    • Noseworthy, Rebecca;
    • Blanco Mejia, Sonia;
    • Kendall, Cyril W. C.;
    • Wolever, Thomas M. S.;
    • Leiter, Lawrence A.;
    • Sievenpiper, John L.
    Publication type:
    Article
    24
    25

    Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 6, p. 1479, doi. 10.1111/dom.13257
    By:
    • Ray, Kausik K.;
    • Letierce, Alexia;
    • Samuel, Rita;
    • Del Prato, Stefano;
    • Leiter, Lawrence A.;
    • Müller‐Wieland, Dirk;
    • Cariou, Bertrand;
    • Colhoun, Helen M.;
    • Henry, Robert R.;
    • Tinahones, Francisco J.;
    • Bujas‐Bobanovic, Maja;
    • Domenger, Catherine
    Publication type:
    Article
    26

    DECLARE‐TIMI 58: Participants’ baseline characteristics.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 5, p. 1102, doi. 10.1111/dom.13217
    By:
    • Raz, Itamar;
    • Mosenzon, Ofri;
    • Cahn, Avivit;
    • Bonaca, Marc P.;
    • Silverman, Michael G.;
    • Bhatt, Deepak L.;
    • Sabatine, Marc S.;
    • Wiviott, Stephen D.;
    • Kato, Eri T.;
    • Leiter, Lawrence A.;
    • McGuire, Darren K.;
    • Wilding, John P. H.;
    • Gause‐Nilsson, Ingrid A. M.;
    • Langkilde, Anna M.;
    • Johansson, Peter A.
    Publication type:
    Article
    27
    28

    Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide ( iGlarLixi) vs insulin glargine and lixisenatide monocomponents

    Published in:
    Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1798, doi. 10.1111/dom.12980
    By:
    • Davies, Melanie J.;
    • Leiter, Lawrence A.;
    • Guerci, Bruno;
    • Grunberger, George;
    • Ampudia‐Blasco, F. Javier;
    • Yu, Christine;
    • Stager, William;
    • Niemoeller, Elisabeth;
    • Souhami, Elisabeth;
    • Rosenstock, Julio
    Publication type:
    Article
    29

    Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2017, v. 19, n. 12, p. 1781, doi. 10.1111/dom.13114
    By:
    • Leiter, Lawrence A.;
    • Cariou, Bertrand;
    • Müller‐Wieland, Dirk;
    • Colhoun, Helen M.;
    • Del Prato, Stefano;
    • Tinahones, Francisco J.;
    • Ray, Kausik K.;
    • Bujas‐Bobanovic, Maja;
    • Domenger, Catherine;
    • Mandel, Jonas;
    • Samuel, Rita;
    • Henry, Robert R.
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36

    Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein.

    Published in:
    JAMA: Journal of the American Medical Association, 2003, v. 290, n. 4, p. 502, doi. 10.1001/jama.290.4.502
    By:
    • Jenkins, David J. A.;
    • Kendall, Cyril W. C.;
    • Marchie, Augustine;
    • Faulkner, Dorothea A.;
    • Wong, Julia M. W.;
    • de Souza, Russell;
    • Emam, Azadeh;
    • Parker, Tina L.;
    • Vidgen, Edward;
    • Lapsley, Karen G.;
    • Trautwein, Elke A.;
    • Josse, Robert G.;
    • Leiter, Lawrence A.;
    • Connelly, Philip W.
    Publication type:
    Article
    37

    Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.

    Published in:
    2021
    By:
    • Szarek, Michael;
    • Bhatt, Deepak L.;
    • Steg, Ph. Gabriel;
    • Cannon, Christopher P.;
    • Leiter, Lawrence A.;
    • McGuire, Darren K.;
    • Lewis, Julia B.;
    • Riddle, Matthew C.;
    • Voors, Adriaan A.;
    • Metra, Marco;
    • Lund, Lars H.;
    • Komajda, Michel;
    • Testani, Jeffrey M.;
    • Wilcox, Christopher S.;
    • Ponikowski, Piotr;
    • Lopes, Renato D.;
    • Banks, Phillip;
    • Tesfaye, Eshetu;
    • Ezekowitz, Justin A.;
    • Verma, Subodh
    Publication type:
    journal article
    38
    39

    Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.

    Published in:
    European Heart Journal, 2015, v. 36, n. 17, p. 1012, doi. 10.1093/eurheartj/ehv043
    By:
    • Stroes, Erik S.;
    • Thompson, Paul D.;
    • Corsini, Alberto;
    • Vladutiu, Georgirene D.;
    • Raal, Frederick J.;
    • Ray, Kausik K.;
    • Roden, Michael;
    • Stein, Evan;
    • Tokgoözoğlu, Lale;
    • Nordestgaard, Børge G.;
    • Bruckert, Eric;
    • De Backer, Guy;
    • Krauss, Ronald M.;
    • Laufs, Ulrich;
    • Santos, Raul D.;
    • Hegele, Robert A.;
    • Hovingh, G. Kees;
    • Leiter, Lawrence A.;
    • Mach, Francois;
    • März, Winfried
    Publication type:
    Article
    40
    41
    42

    A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.

    Published in:
    Cardiovascular Diabetology, 2022, v. 21, n. 1, p. 1, doi. 10.1186/s12933-022-01594-6
    By:
    • Gerstein, Hertzel C.;
    • Ramasundarahettige, Chinthanie;
    • Avezum, Alvero;
    • Basile, Jan;
    • Conget, Ignacio;
    • Cushman, William C.;
    • Dagenais, Gilles R.;
    • Franek, Edward;
    • Lakshmanan, Mark;
    • Lanas, Fernando;
    • Leiter, Lawrence A.;
    • Pogosova, Nana;
    • Probstfield, Jeffrey;
    • Raubenheimer, Peter J.;
    • Riddle, Matthew;
    • Shaw, Jonathan;
    • Sheu, Wayne H.-H.;
    • Temelkova-Kurktschiev, Theodora;
    • Turfanda, Ibrahim;
    • Xavier, Denis
    Publication type:
    Article
    43
    44
    45

    The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.

    Published in:
    Nephrology Dialysis Transplantation, 2020, v. 35, n. 5, p. 895, doi. 10.1093/ndt/gfz294
    By:
    • Opingari, Erika;
    • Verma, Subodh;
    • Connelly, Kim A;
    • Mazer, Cyril David;
    • Teoh, Hwee;
    • Quan, Adrian;
    • Zuo, Fei;
    • Pan, Yi;
    • Bhatt, Deepak L;
    • Zinman, Bernard;
    • Leiter, Lawrence A;
    • Yan, Andrew T;
    • Cherney, David Z I;
    • Gilbert, Richard E
    Publication type:
    Article
    46

    Association of Low- and No-Calorie Sweetened Beverages as a Replacement for Sugar-Sweetened Beverages With Body Weight and Cardiometabolic Risk: A Systematic Review and Meta-analysis.

    Published in:
    JAMA Network Open, 2022, v. 5, n. 3, p. e222092, doi. 10.1001/jamanetworkopen.2022.2092
    By:
    • McGlynn, Néma D.;
    • Khan, Tauseef Ahmad;
    • Wang, Lily;
    • Zhang, Roselyn;
    • Chiavaroli, Laura;
    • Au-Yeung, Fei;
    • Lee, Jennifer J.;
    • Noronha, Jarvis C.;
    • Comelli, Elena M.;
    • Blanco Mejia, Sonia;
    • Ahmed, Amna;
    • Malik, Vasanti S.;
    • Hill, James O.;
    • Leiter, Lawrence A.;
    • Agarwal, Arnav;
    • Jeppesen, Per B.;
    • Rahelić, Dario;
    • Kahleová, Hana;
    • Salas-Salvadó, Jordi;
    • Kendall, Cyril W. C.
    Publication type:
    Article
    47
    48
    49
    50